SCHEMBL829523

SCHEMBL829523

CN1CCN(C(=O)Oc2c(Cl)cc(Cl)cc2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
MAPT P10636 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 2/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
ALOX15 P16050 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
HSP90AA1 P07900 1/20 0.44
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829485 0.85 MAPT (0.63) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL830024 0.83 NPSR1 (0.64) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL830533 0.81 KMT2A (0.59) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL829665 0.78 FAAH (0.53) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL829543 0.77 MAPT (0.46) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL5646336 0.75 LIPE (0.61) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL829345 0.75 LMNA (0.43) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL830651 0.74 SPR (0.60) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL13342918 0.73 CYP1A2 (0.62) KMT2AMEN1MAPTCYP1A2CYP2C19
SCHEMBL4641481 0.73 CA1 (0.42) KMT2AMEN1MAPTCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 HRH4 4270/4885KMT2A 3045/4885MEN1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.